Education
About Us
Working with TipRanks
Follow Us
Lineage Cell Therapeutics, Inc. (LCTX)
:LCTX
LCTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.37 - $1.64
Previous CloseN/A
Volume522.43K
Average Volume (3M)1.62M
Market Cap
$369.94M
Enterprise Value$165.80M
Total Cash (Recent Filing)$42.29M
Total Debt (Recent Filing)$2.15M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Nov 05, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding228,356,300
10 Day Avg. Volume1,889,712
30 Day Avg. Volume1,622,703
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue15.19
Enterprise Value/Gross Profit15.57
Enterprise Value/Ebitda-8.32
Forecast
1Y Price Target
$5.67Price Target Upside254.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company ended the period with $42.3M in cash, which is expected to provide runway into 1Q27 and may be extended by additional collaboration agreements or milestones from Roche.
Partnerships And CollaborationsLineage announced a research collaboration with William Demant Invest to help fund the advancement of ReSonance through preclinical studies for hearing loss.
Product DevelopmentLineage Cell Therapeutics is starting a new islet cell program that could significantly impact hypoimmune cell development in Type 1 diabetes.
Bears Say
Operational RisksOnly a modest investment is needed to reach a go/no-go decision on the new islet cell program.
Lineage Therap News
LCTX FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest stock price was $0.36 and its highest was $1.64 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Lineage Cell Therapeutics, Inc.’s market cap is $369.94M.
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 40 days.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.027 by -$0.103.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. does not currently pay dividends.
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -0.03.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Lineage Cell Therapeutics, Inc. has 228,356,300 shares outstanding.
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.027. Following the earnings report the stock price went up 1.98%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LCTX
Lineage Therap Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.67 (254.38% Upside)
$5.67 (254.38% Upside)
Hedge Fund Trend
Decreased
By 6.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.97%
12-Months-Change
Fundamentals
Return on Equity
-70.12%
Trailing 12-Months
Asset Growth
-11.68%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Therap (LCTX) is a biotechnology company focused on developing innovative cell therapies for the treatment of degenerative diseases and conditions, particularly those affecting the retina. The company specializes in the advancement of pluripotent stem cell technology, which allows for the generation of specialized cells that can potentially restore vision in patients suffering from retinal disorders. Lineage's core products include its lead therapeutic candidates, which are designed to address unmet medical needs in ocular health, as well as other applications in regenerative medicine.
LCTX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with significant progress in the OpRegen and OPC1 programs, including promising clinical results and strategic partnerships. However, financial challenges, including a substantial impairment expense and warrant liabilities, contributed to a notable net loss.View all LCTX earnings summariesLCTX Stock 12 Month Forecast
Average Price Target
$5.67
▲(254.38% Upside)
Technical Analysis
Cellectis SA
―
Editas Medicine
―
Nkarta
―
Neumora Therapeutics, Inc.
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
58.68% Insiders
6.64% Mutual Funds
25.72% Other Institutional Investors
5.76% Public Companies and
Individual Investors